Through high‐throughput screening with functional isogenic BaF3 cells, we found that nintedanib (BIBF 1120), an inhibitor of three angiokinases, VEGFR/PDGFR/FGFR [27] that has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) [28] and non‐small‐cell lung cancer (NSCLC) [29], showed strong inhibition against the effects of multiple mutations in KIT kinase, especially the T670I mutation. Here, KDR is linked to non-small cell lung carcinoma.